Small Cell Lung Cancer Extensive Stage

• CLINICAL_TRIALS research · 2025-11-10
  Clinical Trial Update: Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer [Phase 2]

  This entry provides an update on a Phase 2 trial evaluating talazoparib in combination with low-dose temozolomide for relapsed or refractory…

• CLINICAL_TRIALS research · 2025-07-08
  Clinical Trial Update: A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)

  This document covers a planned retrospective real-world study assessing the efficacy and safety of using Anlotinib hydrochloride in combinat…

• CLINICAL_TRIALS research · 2025-06-15
  Clinical Trial Update: Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy [Phase 2]

  A Phase 2 clinical trial evaluating sintilimab plus anlotinib as second- or later-line therapy for extensive-stage small cell lung cancer th…